AZD8055

Catalog No.S1555

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Cited by 113 Publications

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )
Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )
Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )

EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )
Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )
Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPQXm5qUUN3ME2wMlAzOzNzIN88US=>	MlGxV2FPT0WU
NCI-H720	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfEZ5FKSzVyPUCuNFI6OzhizszN	NIjCfWlUSU6JRWK=
KARPAS-45	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n6emlEPTB;MD6wN\|M4OSEQvF2=	MVPTRW5ITVJ?
EW-3	NV3wXopiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXwc3dGUUN3ME2wMlA1ODV4IN88US=>	NVTxZ3hSW0GQR1XS
SBC-1	NF;tU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYThcG9IUUN3ME2wMlA1PThzIN88US=>	NHvpcWlUSU6JRWK=
NCI-H209	M3TOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXrToVKSzVyPUCuNFU1PTNizszN	NIi3bYlUSU6JRWK=
EoL-1-cell	M3nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTBwME[1Olkh\|ryP	M2DmN3NCVkeHUh?=
H9	MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPITWM2OD1yLkC2OlkzKM7:TR?=	NVjSVYtsW0GQR1XS
AN3-CA	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwMEe5OVEh\|ryP	NFvDXWJUSU6JRWK=
HH	NY\INlk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nVO2lEPTB;MD6wPFAxQSEQvF2=	MYDTRW5ITVJ?
KU812	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XTNGlEPTB;MD6wPFA1OyEQvF2=	M2HKW3NCVkeHUh?=
DU-4475	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3m5R2lEPTB;MD6wPFA1PyEQvF2=	MlPJV2FPT0WU
CTV-1	M2PjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwMEi2OFEh\|ryP	M2HKU3NCVkeHUh?=
BV-173	NGPRWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLJZ5NKSzVyPUCuNFkxPjFizszN	MV3TRW5ITVJ?
ES5	M1jhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4K0PGlEPTB;MD6wPVM2KM7:TR?=	MoPjV2FPT0WU
G-402	M1rOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnuRWxzUUN3ME2wMlA6QThizszN	MnvTV2FPT0WU
MV-4-11	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnTTXA{UUN3ME2wMlExOzR5IN88US=>	M1\PfnNCVkeHUh?=
NB69	M37zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwMUO1JO69VQ>?	NX7wfGI4W0GQR1XS
EGI-1	M4XCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nmTGlEPTB;MD6xN\|U{OSEQvF2=	MXfTRW5ITVJ?
EW-18	NV7YOYNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTwb5U5UUN3ME2wMlE1ODd\|IN88US=>	NX:wR21mW0GQR1XS
ME-180	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTBwMUS2PFEh\|ryP	M3\QTHNCVkeHUh?=
D-283MED	NYLpZ4ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXu4cpVRUUN3ME2wMlE1PzJ\|IN88US=>	MlvkV2FPT0WU
NB14	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\Sd2lEPTB;MD6xOlQ1PyEQvF2=	MlL4V2FPT0WU
Ramos-2G6-4C10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfSSZBGUUN3ME2wMlE3QTh\|IN88US=>	MlK0V2FPT0WU
NBsusSR	M37qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLHTWM2OD1yLkG3NFE6KM7:TR?=	MYnTRW5ITVJ?
LAMA-84	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fobmlEPTB;MD6xPFA{OiEQvF2=	Mn7HV2FPT0WU
NCI-H1581	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DlTmlEPTB;MD6xPFk3PiEQvF2=	MmDlV2FPT0WU
A204	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\COmlEPTB;MD6xPFk4KM7:TR?=	NI\UZ41USU6JRWK=
A549	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjhSldvUUN3ME2wMlE6PTVizszN	M3nGN3NCVkeHUh?=
CAL-51	NFPNSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W3NGlEPTB;MD6xPVY2OSEQvF2=	MonnV2FPT0WU
NKM-1	M3;ae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Xy[mlEPTB;MD6yNFAzQSEQvF2=	NHOzPGFUSU6JRWK=
LoVo	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLCTWM2OD1yLkKwNlAzKM7:TR?=	NW\LXHZJW0GQR1XS
HAL-01	NF6xVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DLN2lEPTB;MD6yNFI6PyEQvF2=	MUPTRW5ITVJ?
HCC2218	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDkTWM2OD1yLkKwOlg5KM7:TR?=	MmrKV2FPT0WU
BEN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXSWYFrUUN3ME2wMlIyOjl\|IN88US=>	MnHhV2FPT0WU
LC-2-ad	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXaTWM2OD1yLkKyNFg1KM7:TR?=	NWD4V\|J1W0GQR1XS
LXF-289	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nnemlEPTB;MD6yOVA1OSEQvF2=	M2fsSnNCVkeHUh?=
HGC-27	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMk[0NVQh\|ryP	M2ixXXNCVkeHUh?=
LK-2	M3\PdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj6[mZKSzVyPUCuNlY5OjRizszN	NF7DWFhUSU6JRWK=
CTB-1	M4P5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmG0TWM2OD1yLkK3NlE2KM7:TR?=	M3zKXXNCVkeHUh?=
697	MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEK0RWVKSzVyPUCuNlc{PjdizszN	NH;jdoRUSU6JRWK=
ES7	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPkUGNZUUN3ME2wMlI4Ozh\|IN88US=>	M3\CZnNCVkeHUh?=
MG-63	NEO2XYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTBwMke0NFch\|ryP	Mlv4V2FPT0WU
T47D	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXHcWRXUUN3ME2wMlI4PDd3IN88US=>	NHjYVIRUSU6JRWK=
RPMI-8226	NVHWO\|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTBwMki1PFkh\|ryP	MVfTRW5ITVJ?
NCI-H292	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{SwRWlEPTB;MD6yPVE3PCEQvF2=	MlXmV2FPT0WU
HT	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;kNGlEPTB;MD6yPVM5KM7:TR?=	MWPTRW5ITVJ?
A3-KAW	NGrpbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDtTGltUUN3ME2wMlI6PzRizszN	NH7oS5ZUSU6JRWK=
LB2241-RCC	M3OzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHWOHpKSzVyPUCuN\|AyQThizszN	M{DnS3NCVkeHUh?=
BB65-RCC	NVzpRldXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXqTWM2OD1yLkOwPFA2KM7:TR?=	NI[xd5BUSU6JRWK=
G-401	NYXwOlJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvJbJBKSzVyPUCuN\|A6QDZizszN	MV\TRW5ITVJ?
TYK-nu	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILIbGNKSzVyPUCuN\|E5PjRizszN	M3;xeHNCVkeHUh?=
NCI-SNU-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\xTWM2OD1yLkOyN\|MyKM7:TR?=	MmK4V2FPT0WU
CHL-1	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwM{K3NFMh\|ryP	NIWyXpNUSU6JRWK=
P30-OHK	NIW5fJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;FTWM2OD1yLkOyO\|A2KM7:TR?=	NFnqcWVUSU6JRWK=
PA-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTETWM2OD1yLkOzOlE6KM7:TR?=	MWfTRW5ITVJ?
LB1047-RCC	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\wVVFKSzVyPUCuN\|QxPDdizszN	NWjGNYx6W0GQR1XS
EM-2	M2rJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHtdohKSzVyPUCuN\|QyQDhizszN	NXTEO5l[W0GQR1XS
VA-ES-BJ	M4HMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwM{SyOlgh\|ryP	Mn\NV2FPT0WU
NCI-H520	NF;FT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTLPZhPUUN3ME2wMlM1QDN2IN88US=>	M3XtRnNCVkeHUh?=
ECC10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LyTGlEPTB;MD6zOVA{PSEQvF2=	MXjTRW5ITVJ?
LNCaP-Clone-FGC	M{PzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUP2VGdvUUN3ME2wMlM2OzF2IN88US=>	M4naWnNCVkeHUh?=
ES8	NXfEbVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwM{[1OVMh\|ryP	NGDWPJRUSU6JRWK=
HuO-3N1	M{[3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTpUY9bUUN3ME2wMlM5Ozd7IN88US=>	MX7TRW5ITVJ?
L-363	NXvBSHN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[4V2lKSzVyPUCuN\|kxOjZizszN	NVHoSpJUW0GQR1XS
SK-LU-1	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mke1TWM2OD1yLkO5NlA5KM7:TR?=	NFHreodUSU6JRWK=
MCF7	NFrHcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVG4VWxHUUN3ME2wMlQxPTNizszN	MojrV2FPT0WU
HuO9	NVHIOI5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIT3TJhKSzVyPUCuOFA3PjdizszN	MmrTV2FPT0WU
BHT-101	NFviZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\TTWM2OD1yLkSwO\|g4KM7:TR?=	MlzvV2FPT0WU
MZ2-MEL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTBwNEC4PFIh\|ryP	M1\PRXNCVkeHUh?=
NOS-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPUTWM2OD1yLkSxNFc1KM7:TR?=	MVrTRW5ITVJ?
NEC8	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYi4eVM4UUN3ME2wMlQyPjl3IN88US=>	NX2zeHRyW0GQR1XS
COR-L88	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrvO4ZHUUN3ME2wMlQzOjZ5IN88US=>	NXfQe2NxW0GQR1XS
MFM-223	M1z2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwNEK2NVch\|ryP	MofiV2FPT0WU
HSC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Gx[2lEPTB;MD60NlkxQCEQvF2=	M2fHUnNCVkeHUh?=
OVCAR-5	M1jZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoOxTWM2OD1yLkSyPVM{KM7:TR?=	M3\0NnNCVkeHUh?=
MFE-280	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzRTWM2OD1yLkSzNFMzKM7:TR?=	Mn3HV2FPT0WU
KP-N-YS	NV;KOHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPCV41jUUN3ME2wMlQ{ODdizszN	M2C5[3NCVkeHUh?=
EPLC-272H	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWOybY1DUUN3ME2wMlQ{ODd5IN88US=>	MXvTRW5ITVJ?
KE-37	M13VdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jZT2lEPTB;MD60N\|I1PyEQvF2=	NGq2TlhUSU6JRWK=
HuH-7	NVvjS\|dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELQ[4lKSzVyPUCuOFM{PzJizszN	MUXTRW5ITVJ?
CHP-212	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDmXHhKSzVyPUCuOFM3QTdizszN	MlfrV2FPT0WU
SK-MES-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DTbmlEPTB;MD60N\|g1QCEQvF2=	NWXMd2J4W0GQR1XS
SJSA-1	NIHmTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrHOmJKSzVyPUCuOFQ2PTRizszN	MYrTRW5ITVJ?
QIMR-WIL	NV;zPZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrM[mpKSzVyPUCuOFUyPSEQvF2=	MlraV2FPT0WU
ES4	M17qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnuUo54UUN3ME2wMlQ2OzN4IN88US=>	MlS2V2FPT0WU
TI-73	M1rPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PPfmlEPTB;MD60OVY5PiEQvF2=	M2nsNXNCVkeHUh?=
COLO-684	NYLqU2FWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzBUFhLUUN3ME2wMlQ2PzJ4IN88US=>	NXXt[otQW0GQR1XS
GCIY	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TBWmlEPTB;MD60OVc2PCEQvF2=	NES0emxUSU6JRWK=
JVM-3	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fRZ2lEPTB;MD60OlI6OiEQvF2=	NI\xbXJUSU6JRWK=
MPP-89	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYKwTJRbUUN3ME2wMlQ3QTR5IN88US=>	MmfvV2FPT0WU
M14	M3[0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTBwNEexO{DPxE1?	M1nMXHNCVkeHUh?=
SW962	M1WwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfIRoh{UUN3ME2wMlQ4OTlizszN	M3;JUnNCVkeHUh?=
VM-CUB-1	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjldZdKSzVyPUCuOFczQDZizszN	MYrTRW5ITVJ?
A101D	NVL5WYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\pZ2lEPTB;MD60PFk3QCEQvF2=	NHj0XXNUSU6JRWK=
DB	NXHLRllxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLXTWM2OD1yLkWwNFIyKM7:TR?=	M375ZXNCVkeHUh?=
KNS-62	NWLzUlRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvYVVVKSzVyPUCuOVA2PjhizszN	MWLTRW5ITVJ?
NCI-H460	NYTtdGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XSe2lEPTB;MD61NFU6PyEQvF2=	MnW3V2FPT0WU
MDA-MB-361	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTKfHlKSzVyPUCuOVA5PyEQvF2=	M3m5VnNCVkeHUh?=
DOK	NV7tb29ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTCeJIyUUN3ME2wMlUyOzN\|IN88US=>	M2j3fnNCVkeHUh?=
CAL-39	M1LyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnK4TWM2OD1yLkWyNlY5KM7:TR?=	Mn7ZV2FPT0WU
HT-1080	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofOTWM2OD1yLkWyOVQ{KM7:TR?=	NVLHOYNZW0GQR1XS
GR-ST	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rYWmlEPTB;MD61N\|AyPSEQvF2=	MkSwV2FPT0WU
J-RT3-T3-5	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTBwNUOxPVUh\|ryP	NV3BcJFzW0GQR1XS
NCI-H1793	NX7RTpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvkbWJGUUN3ME2wMlU{PDR5IN88US=>	Mmf1V2FPT0WU
NCI-H1355	NHHlSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoS2TWM2OD1yLkWzPFc5KM7:TR?=	NVjreVhGW0GQR1XS
YH-13	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrWZVZKSzVyPUCuOVQ6OzhizszN	NUfJfYR3W0GQR1XS
LOXIMVI	NIHaOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwNUWxNlMh\|ryP	M4W1b3NCVkeHUh?=
ES1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHFTWM2OD1yLkW1OVE5KM7:TR?=	NVTzWlFoW0GQR1XS
GAMG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3j[Ic6UUN3ME2wMlU2PjV6IN88US=>	M{TOXnNCVkeHUh?=
SK-MEL-28	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFn0OVlKSzVyPUCuOVU6OSEQvF2=	NFjkTGZUSU6JRWK=
KG-1	M4jBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fjeGlEPTB;MD61Olg5PCEQvF2=	MYTTRW5ITVJ?
HOS	NWPGSGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnsTWM2OD1yLkW3NVkzKM7:TR?=	NF:5SJJUSU6JRWK=
PANC-08-13	NV3VOJpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rHW2lEPTB;MD61O\|M5QSEQvF2=	NXPDWFY{W0GQR1XS
SW780	NXjmWGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HhTWlEPTB;MD61O\|U6PSEQvF2=	MX;TRW5ITVJ?
MDA-MB-175-VII	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjYfnR3UUN3ME2wMlU4PzRzIN88US=>	NHvqRWtUSU6JRWK=
MSTO-211H	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3OWmtKSzVyPUCuOVc4PTFizszN	NX3OSYxZW0GQR1XS
ML-2	NU\J[I9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTBwNUi0O\|gh\|ryP	NYHpPVRYW0GQR1XS
SCC-4	NVjSPXNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwNUi1OFEh\|ryP	MmHiV2FPT0WU
NCI-H1048	M4PWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2KzZmlEPTB;MD61PFY1PSEQvF2=	NVH3cIRyW0GQR1XS
NCI-H28	NYTYUHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnFc4JyUUN3ME2wMlU5Pjd3IN88US=>	M{j4ZXNCVkeHUh?=
BCPAP	M1nDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjRd3ZKSzVyPUCuOVg4QTFizszN	M3LjSHNCVkeHUh?=
PC-14	NHnIVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS5TWM2OD1yLkW4PVch\|ryP	MXPTRW5ITVJ?
OAW-42	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XCUmlEPTB;MD61PVE3OiEQvF2=	M1zDeHNCVkeHUh?=
IA-LM	NIjOTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzMeYxKSzVyPUCuOVk3ODlizszN	MVTTRW5ITVJ?
Hs-578-T	NVvoVHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M370UmlEPTB;MD61PVg2OSEQvF2=	M{[zVnNCVkeHUh?=
H4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjDdZBKSzVyPUCuOlAxQTRizszN	MWrTRW5ITVJ?
HL-60	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwNkCzOVEh\|ryP	NETQTYpUSU6JRWK=
NCI-H1437	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTBwNkC2NVkh\|ryP	MYjTRW5ITVJ?
KGN	NETPSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljwTWM2OD1yLk[xNFQ6KM7:TR?=	M4T3SHNCVkeHUh?=
NCI-H2452	NYL1cphoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rBTWlEPTB;MD62NVkyPyEQvF2=	NGi5To1USU6JRWK=
BFTC-905	NWn4XI86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXj2Z5ZrUUN3ME2wMlYzOTJ4IN88US=>	NUj4VnZmW0GQR1XS
CAMA-1	NYLwU\|FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHZfJlKSzVyPUCuOlIyPTJizszN	M4nwd3NCVkeHUh?=
SK-NEP-1	M2noOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq2OWJKSzVyPUCuOlI2ODJizszN	MVvTRW5ITVJ?
NCI-H522	M37vTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\zbGlEPTB;MD62Nlk6OiEQvF2=	NYe2cIY{W0GQR1XS
SW1710	NYm2cllMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVr1cm9zUUN3ME2wMlY{OTZ5IN88US=>	MoD2V2FPT0WU
RVH-421	NWq4b4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwNkO2N\|kh\|ryP	NFjsUpdUSU6JRWK=
SK-MEL-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGr1XJZKSzVyPUCuOlQyPTNizszN	NFzTepFUSU6JRWK=
KYSE-150	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTBwNk[xPFYh\|ryP	M3[zWHNCVkeHUh?=
MOLT-13	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDi[oFKSzVyPUCuOlY2OzdizszN	NGrNXW5USU6JRWK=
SK-OV-3	M4PGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rMTGlEPTB;MD62O\|E5PyEQvF2=	NVPhZ5plW0GQR1XS
IGROV-1	NUDUUnljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwNke0OUDPxE1?	NYPqUFFiW0GQR1XS
MOLT-4	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rQcmlEPTB;MD62O\|Y5QSEQvF2=	MonRV2FPT0WU
MEL-HO	M2S1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fRbGlEPTB;MD62O\|c2OiEQvF2=	NFG5fo5USU6JRWK=
MDA-MB-157	NXfmWWl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjrdHdKSzVyPUCuOlc5OSEQvF2=	MoLmV2FPT0WU
MN-60	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnroTWM2OD1yLk[3PFQ3KM7:TR?=	MoPWV2FPT0WU
EFO-27	NFzCVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTBwNke5O\|kh\|ryP	MWDTRW5ITVJ?
HO-1-N-1	M1HoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTBwNkiwOlQh\|ryP	M2njfnNCVkeHUh?=
TE-5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf0PYFKSzVyPUCuOlg1ODVizszN	NYDMXWx5W0GQR1XS
EW-22	NYPEfpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwNki0OFQh\|ryP	MkjqV2FPT0WU
SW982	NILlZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmezTWM2OD1yLk[4OVAyKM7:TR?=	MXLTRW5ITVJ?
SF295	NYnEdpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjCTWM2OD1yLk[4OVA4KM7:TR?=	NGDp[3RUSU6JRWK=
WM-115	M{nwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jVO2lEPTB;MD62PFkzPCEQvF2=	MkDNV2FPT0WU
COLO-800	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTBwNkm4NVMh\|ryP	MX7TRW5ITVJ?
NTERA-S-cl-D1	NH3PbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2q1emlEPTB;MD63NFA3OyEQvF2=	NFjWXFlUSU6JRWK=
NCI-H1648	NWe5VWZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PoVmlEPTB;MD63NFE4OyEQvF2=	NF\aOVhUSU6JRWK=
NB5	NVfYcZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1f6V2lEPTB;MD63NFMyQSEQvF2=	NYPlcVJQW0GQR1XS
ATN-1	NHnqSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTRTWM2OD1yLkewOVkh\|ryP	M3TRTHNCVkeHUh?=
NUGC-3	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXRTWM2OD1yLkewOlkyKM7:TR?=	MYnTRW5ITVJ?
22RV1	M1TybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXnR2hKSzVyPUCuO\|A4OTdizszN	NV3Qc5QyW0GQR1XS
8305C	NFGwUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLBdoRKSzVyPUCuO\|A4PTVizszN	NH7TWIhUSU6JRWK=
EFM-19	NFf4T5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwN{C4OFch\|ryP	M4TuXnNCVkeHUh?=
PC-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHXTWM2OD1yLkeyNlMh\|ryP	NGDiW4tUSU6JRWK=
C32	NVLE[JR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwN{K0PFQh\|ryP	NG[3dmZUSU6JRWK=
MC-IXC	NFvOcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnsTWM2OD1yLkeyO\|E5KM7:TR?=	Ml3mV2FPT0WU
OMC-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XvbmlEPTB;MD63Nlc{QCEQvF2=	NYHBTGpuW0GQR1XS
HTC-C3	NF[zVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwN{OxO\|Ih\|ryP	NXLUXYF5W0GQR1XS
RPMI-7951	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPqTWM2OD1yLkezOVM{KM7:TR?=	NG\Eb21USU6JRWK=
AsPC-1	NV;LNJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXDTWM2OD1yLkezO\|k2KM7:TR?=	NGHucpRUSU6JRWK=
CAKI-1	NVvTUZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfuTWM2OD1yLke0OlI6KM7:TR?=	NWixb5ZFW0GQR1XS
MHH-PREB-1	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;w[3FGUUN3ME2wMlc1PzN4IN88US=>	M{DQ[nNCVkeHUh?=
HLE	NEDH[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPDW4lTUUN3ME2wMlc1QDR2IN88US=>	M2WwbnNCVkeHUh?=
A375	NWHQXoMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTBwN{WxPVMh\|ryP	MUfTRW5ITVJ?
RS4-11	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTBwN{W5OFMh\|ryP	M{f0[nNCVkeHUh?=
U-2-OS	M{XIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnId5JKSzVyPUCuO\|U6PyEQvF2=	NV6xUJRnW0GQR1XS
NCI-H747	NHy0UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET4c5BKSzVyPUCuO\|U6QTFizszN	NEDFc4lUSU6JRWK=
NCI-H1623	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfBRXNKSzVyPUCuO\|YzPjFizszN	M3LIOHNCVkeHUh?=
DMS-273	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vJNmlEPTB;MD63OlkzOiEQvF2=	NEO2TYxUSU6JRWK=
PSN1	M4jk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwN{ewOVch\|ryP	MmjzV2FPT0WU
LU-99A	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjQS3ptUUN3ME2wMlc4PjR7IN88US=>	M{DLWXNCVkeHUh?=
CAL-12T	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTBwN{iwNlkh\|ryP	MoCyV2FPT0WU
KYSE-140	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnr0TWM2OD1yLke4NVY5KM7:TR?=	NUG3ZWZLW0GQR1XS
VMRC-RCZ	NWjUWJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGm2bnpKSzVyPUCuO\|g1QDJizszN	Mn3CV2FPT0WU
Ca9-22	NHrYdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rpdmlEPTB;MD63PFc{PiEQvF2=	NHjIOXdUSU6JRWK=
NCI-H1563	M2HjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2m2UWlEPTB;MD63PFkzPiEQvF2=	NGjjU5BUSU6JRWK=
NCI-H650	NGO2V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zJPGlEPTB;MD63PVE1PCEQvF2=	M2DQT3NCVkeHUh?=
DOHH-2	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3neZBKSzVyPUCuO\|k{OyEQvF2=	MmHIV2FPT0WU
OE33	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwN{m5NVQh\|ryP	NV3uXJRZW0GQR1XS
CAL-62	NEm3VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rlcmlEPTB;MD63PVkzPCEQvF2=	MX7TRW5ITVJ?
NCI-H1770	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvwOmVKSzVyPUCuPFAzOSEQvF2=	MWDTRW5ITVJ?
SN12C	M3iwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnFUHVKSzVyPUCuPFA3PjhizszN	MlTqV2FPT0WU
HPAF-II	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrBfHNkUUN3ME2wMlgxPzl2IN88US=>	NEHKZWlUSU6JRWK=
SNU-423	M1\ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7Pbpd6UUN3ME2wMlgyPDJ{IN88US=>	M1zobXNCVkeHUh?=
A704	NIXpfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7wT4lOUUN3ME2wMlgyPzl6IN88US=>	NV3JUW9vW0GQR1XS
OVCAR-4	M1nNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPtcm1TUUN3ME2wMlgyQTFzIN88US=>	NF;4RW5USU6JRWK=
NCI-H2347	MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXNTWM2OD1yLkiyOFAyKM7:TR?=	M2KwfHNCVkeHUh?=
OCUB-M	NWPDWYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17KbGlEPTB;MD64NlY4PSEQvF2=	NGTG[mZUSU6JRWK=
KYSE-450	NW\VZVFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;uR\|hKSzVyPUCuPFI4OjVizszN	MVrTRW5ITVJ?
PFSK-1	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwOEOwN\|kh\|ryP	NY\K[nFZW0GQR1XS
A431	NULze5p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrMTWM2OD1yLkizNVE3KM7:TR?=	NW\iN5lrW0GQR1XS
MHH-ES-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;HTWM2OD1yLkizOFU4KM7:TR?=	MVnTRW5ITVJ?
HD-MY-Z	NVPsclNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3qyR2lEPTB;MD64OFA6OiEQvF2=	NIHyVWVUSU6JRWK=
RT-112	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXSTWM2OD1yLki0PVM4KM7:TR?=	MV;TRW5ITVJ?
KU-19-19	M{PJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37KbGlEPTB;MD64OVEzOSEQvF2=	M4nPN3NCVkeHUh?=
HCC1569	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwOEWyNFch\|ryP	MVfTRW5ITVJ?
RPMI-8866	NGjTSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X0[2lEPTB;MD64OVgzOiEQvF2=	MVjTRW5ITVJ?
CAL-120	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3oVHhKSzVyPUCuPFYxPDFizszN	MVHTRW5ITVJ?
CAL-33	NVPpcGR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwOE[0PVUh\|ryP	MmP0V2FPT0WU
RKO	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTBwOE[4NVch\|ryP	MVfTRW5ITVJ?
HCC1419	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TCRWlEPTB;MD64OlkzQCEQvF2=	M33pV3NCVkeHUh?=
CP50-MEL-B	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;FTWM2OD1yLki4N\|g1KM7:TR?=	NEHJSo9USU6JRWK=
BPH-1	NX;UVYZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTBwOEizPVUh\|ryP	NUnW[WNSW0GQR1XS
SF126	NIPNWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIe5RmpKSzVyPUCuPFg4OTRizszN	MkG3V2FPT0WU
BHY	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTBwOEi3N\|Qh\|ryP	NHjyW\|RUSU6JRWK=
BxPC-3	M4\YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVz4SnRiUUN3ME2wMlg5QDN\|IN88US=>	MoHVV2FPT0WU
ETK-1	M4\NTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W3RmlEPTB;MD64PVM4OiEQvF2=	MoftV2FPT0WU
NCI-H1573	NVrk[GNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDqe2tKSzVyPUCuPVAzOjlizszN	MmT6V2FPT0WU
C-33-A	NXj2TGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHK5fZFKSzVyPUCuPVA1PDJizszN	NG\6SYpUSU6JRWK=
UACC-893	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LzOmlEPTB;MD65Nlg2PSEQvF2=	NHn3NYNUSU6JRWK=
RXF393	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXVTWM2OD1yLkmyPFk4KM7:TR?=	MmT2V2FPT0WU
MIA-PaCa-2	NGntW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\pTWM2OD1yLkmyPVIzKM7:TR?=	MX;TRW5ITVJ?
HCC1806	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LT[WlEPTB;MD65N\|I2PiEQvF2=	NHrCdXZUSU6JRWK=
DMS-114	NWTLdm82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\ZSlNKSzVyPUCuPVM3PzdizszN	MWPTRW5ITVJ?
MOLT-16	NX\hWXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fTR2lEPTB;MD65N\|g1PSEQvF2=	Mnr3V2FPT0WU
ACN	M1rlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwOUSyO\|ch\|ryP	MmrMV2FPT0WU
SNU-449	NXPkeIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwOUW5NlQh\|ryP	MYPTRW5ITVJ?
A427	NF3oSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwOU[xPVgh\|ryP	MnjMV2FPT0WU
DEL	NGP1OpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfEV4xKSzVyPUCuPVY4PzNizszN	M1vvTXNCVkeHUh?=
NCI-H1792	NF:2dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwOUexNFEh\|ryP	MXnTRW5ITVJ?
A2058	NUfUR4E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XIN2lEPTB;MD65O\|M3KM7:TR?=	MUDTRW5ITVJ?
SW13	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwOUizPVIh\|ryP	M3fQOnNCVkeHUh?=
T98G	M{\p[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37ifmlEPTB;MT6wNVM3PCEQvF2=	M4XxOXNCVkeHUh?=
LU-134-A	NXrjOYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\iR4xJUUN3ME2xMlAzPjd3IN88US=>	M4raTXNCVkeHUh?=
GI-ME-N	NXrZZ3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFwMEK4Nlch\|ryP	NX;2OmpKW0GQR1XS
D-423MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfmTWM2OD1zLkCyPVY{KM7:TR?=	MXLTRW5ITVJ?
PANC-03-27	NHf2T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojNTWM2OD1zLkCzNVQyKM7:TR?=	NXvJc2RRW0GQR1XS
P12-ICHIKAWA	NV7wVYFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX0TWM2OD1zLkCzOFA3KM7:TR?=	NHXBUG5USU6JRWK=
SCH	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjGWpRDUUN3ME2xMlA{PDVizszN	NIrQeItUSU6JRWK=
D-566MG	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPn[GNKSzVyPUGuNFY4OjZizszN	MlLWV2FPT0WU
OS-RC-2	NHu1R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFwMEe5OEDPxE1?	NFvlVIdUSU6JRWK=
KOSC-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XZZmlEPTB;MT6wPFAzOSEQvF2=	Ml7aV2FPT0WU
SH-4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILMfppKSzVyPUGuNFg1OzFizszN	MlTRV2FPT0WU
786-0	NI\jVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwMEi5N\|Qh\|ryP	M1rVZnNCVkeHUh?=
Mewo	NHPEPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;EWFVKSzVyPUGuNFkzPDhizszN	MUPTRW5ITVJ?
AGS	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTFwMEm0OVkh\|ryP	MVvTRW5ITVJ?
Daoy	NEjRZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFwMEm2Nlgh\|ryP	NIPsNXdUSU6JRWK=
SW48	NVPt[mZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\LNmlEPTB;MT6xNFkyOSEQvF2=	MnGxV2FPT0WU
KYSE-180	NX\qVW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zpSGlEPTB;MT6xNVAzOSEQvF2=	MonrV2FPT0WU
NH-12	NYDiO4pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFwMUGyN\|ch\|ryP	MVvTRW5ITVJ?
BE-13	NIDqW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPZTWM2OD1zLkGxO\|U6KM7:TR?=	MnL3V2FPT0WU
ES3	M2rXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHzc3BOUUN3ME2xMlE{OTdzIN88US=>	NXfmRpR{W0GQR1XS
NCI-H1092	NGLq[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrJO4tMUUN3ME2xMlE{PCEQvF2=	Mki2V2FPT0WU
NCI-H1755	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFwMUO5OFEh\|ryP	NH;OUWJUSU6JRWK=
EKVX	NXTHe4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7G[JVEUUN3ME2xMlE1ODBzIN88US=>	NEDQVFNUSU6JRWK=
NB13	M{HQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFWxfpJKSzVyPUGuNVQ1PSEQvF2=	Mo\VV2FPT0WU
NCI-H2405	NYT4WY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWqzc\|JVUUN3ME2xMlE1PTd2IN88US=>	MmrGV2FPT0WU
LS-411N	M36x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwMUWwNVch\|ryP	NUji[3RPW0GQR1XS
MDA-MB-453	MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETtPXRKSzVyPUGuNVU3OjRizszN	NFuzTIdUSU6JRWK=
SCC-15	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLQTWM2OD1zLkG2PVU3KM7:TR?=	NV;u[FhlW0GQR1XS
C2BBe1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXwOYRKSzVyPUGuNVcxPTZizszN	NXLvXY1iW0GQR1XS
HT-144	NX;UOnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\rTWM2OD1zLkG3NFch\|ryP	M3rBc3NCVkeHUh?=
HEC-1	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TDe2lEPTB;MT6xO\|YzPyEQvF2=	NV3J[mdmW0GQR1XS
HCE-T	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rWXGlEPTB;MT6xO\|k5OyEQvF2=	NVrz[mhKW0GQR1XS
IST-MEL1	M2HJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHOTWM2OD1zLkG5NFgzKM7:TR?=	NFSzdmRUSU6JRWK=
Detroit562	NYLVSoxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLZXphKSzVyPUGuNVk1OzlizszN	M4\LbHNCVkeHUh?=
A4-Fuk	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\kOWlEPTB;MT6yNFQ1OSEQvF2=	NFzFRXhUSU6JRWK=
HDLM-2	MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFwMkGzNlYh\|ryP	NETaOWJUSU6JRWK=
MKN7	M{i0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWe3XoFTUUN3ME2xMlIyPzB{IN88US=>	NGPhTldUSU6JRWK=
MDA-MB-415	MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHRdpZKUUN3ME2xMlIyPzB{IN88US=>	NHyxd\|VUSU6JRWK=
BT-20	M3\UVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwMkK0OFQh\|ryP	MmLXV2FPT0WU
NCI-H2030	M3P4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PTVWlEPTB;MT6yOFExPiEQvF2=	NYCyPFQzW0GQR1XS
LS-123	NWPjN2JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfzfYJKSzVyPUGuNlQ4PTNizszN	NHG1NFBUSU6JRWK=
SK-MEL-3	NX\3[md3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rVV2lEPTB;MT6yOFc4PiEQvF2=	MoXIV2FPT0WU
KS-1	M1rrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoriTWM2OD1zLkK1NVcyKM7:TR?=	NFvDO5RUSU6JRWK=
LU-65	NF;BNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTFwMkW2NFYh\|ryP	NH3vTJRUSU6JRWK=
NCI-H596	NFT3U\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEG5SZNKSzVyPUGuNlU6OjlizszN	NGjtdWtUSU6JRWK=
KYSE-410	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTFwMkewNVQh\|ryP	NWfUcZVSW0GQR1XS
NCI-H2228	NH\DV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlq3TWM2OD1zLkK3NVY4KM7:TR?=	NFnG[G5USU6JRWK=
LN-405	NXfJR24zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\C[JpKSzVyPUGuNlgxOjFizszN	NVrzOXk5W0GQR1XS
8505C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwMki4NlMh\|ryP	MVPTRW5ITVJ?
BFTC-909	M2PjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULXNVJTUUN3ME2xMlI6PDN2IN88US=>	MmLMV2FPT0WU
OC-314	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zucGlEPTB;MT6yPVkzQSEQvF2=	MXrTRW5ITVJ?
NMC-G1	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTFwM{GxN\|Uh\|ryP	M1uye3NCVkeHUh?=
SKG-IIIa	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHxUpF[UUN3ME2xMlMyPDJ6IN88US=>	NXHONFJRW0GQR1XS
GAK	M3\pTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jCOmlEPTB;MT6zNVg2QCEQvF2=	NXPST4VJW0GQR1XS
D-263MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFSwNmdKSzVyPUGuN\|I3PDFizszN	Ml;vV2FPT0WU
NCI-H446	NI\4UJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHNe4hbUUN3ME2xMlMzQTB{IN88US=>	M4rYVXNCVkeHUh?=
TGBC1TKB	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTFwM{K5PVgh\|ryP	NVjLbnlWW0GQR1XS
GCT	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnyPYRkUUN3ME2xMlM1OzR3IN88US=>	NVewXlNyW0GQR1XS
COR-L23	NFiwbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYe3RmtwUUN3ME2xMlM1QDR3IN88US=>	MUXTRW5ITVJ?
TK10	MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLYTndJUUN3ME2xMlM2Pzl5IN88US=>	NYHJNW9TW0GQR1XS
ES6	M4TGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e2O2lEPTB;MT6zOlM4PiEQvF2=	M1fZdXNCVkeHUh?=
SW1088	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjzRlNKUUN3ME2xMlM3PjF{IN88US=>	MoDyV2FPT0WU
AM-38	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXOTWM2OD1zLkO3NVk6KM7:TR?=	MYLTRW5ITVJ?
CHP-134	NICwXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\6VZJKSzVyPUGuN\|c5PDRizszN	M3zUW3NCVkeHUh?=
SW872	M3nZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTmZpVHUUN3ME2xMlM5PTV3IN88US=>	MnLmV2FPT0WU
LB831-BLC	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFwM{mwOlch\|ryP	M3PpdHNCVkeHUh?=
TE-12	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rRWmlEPTB;MT60NFYxOSEQvF2=	MXHTRW5ITVJ?
LCLC-97TM1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;0TWM2OD1zLkSxNFQ3KM7:TR?=	M{\ETnNCVkeHUh?=
HCT-116	NF3nfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHmwUVZKSzVyPUGuOFI5PTRizszN	NWTqUW94W0GQR1XS
ALL-PO	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nLXGlEPTB;MT60N\|c4PCEQvF2=	M{js[3NCVkeHUh?=
EW-16	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXTdGV2UUN3ME2xMlQ{QDR{IN88US=>	MmDYV2FPT0WU
NCI-H661	NXHmUIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFwNES3O\|Uh\|ryP	MnjMV2FPT0WU
TE-8	M4\SPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfoT4JKSzVyPUGuOFU2PiEQvF2=	NXLTdXdwW0GQR1XS
TCCSUP	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{izemlEPTB;MT60Olk3KM7:TR?=	MnmyV2FPT0WU
SW1990	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTFwNEe1N\|Mh\|ryP	NIrpNmJUSU6JRWK=
UM-UC-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT4TWM2OD1zLkS3Olc2KM7:TR?=	NEjUeIpUSU6JRWK=
HuP-T4	NFnJbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP4SXdNUUN3ME2xMlQ5PjB5IN88US=>	NV24V3VZW0GQR1XS
NCI-H1299	NHzpNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zEcGlEPTB;MT61NFA5PiEQvF2=	MmLWV2FPT0WU
RO82-W-1	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Lrc2lEPTB;MT61NlA5OSEQvF2=	Mm\tV2FPT0WU
Becker	NX3DbJJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP5TWM2OD1zLkWyNVg4KM7:TR?=	NYPOeI9[W0GQR1XS
SNU-387	M1vPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jHRWlEPTB;MT61NlI1OSEQvF2=	MmfYV2FPT0WU
CAL-85-1	NYTZOmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjOTWM2OD1zLkWyOVk6KM7:TR?=	NUCyNW5pW0GQR1XS
647-V	NEXCTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\tbGJKSzVyPUGuOVM5QCEQvF2=	M{jacnNCVkeHUh?=
SBC-5	M3\TOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDZXlJjUUN3ME2xMlU1PTl\|IN88US=>	NHnGcZBUSU6JRWK=
NCI-H23	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fJb2lEPTB;MT61OVcyPCEQvF2=	MYrTRW5ITVJ?
CGTH-W-1	NEnLRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvuTWM2OD1zLkW1PFE6KM7:TR?=	MWXTRW5ITVJ?
SK-N-FI	NUTHTFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlr4TWM2OD1zLkW1PVA5KM7:TR?=	NV7yTYVCW0GQR1XS
KM-H2	M2exOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rNc2lEPTB;MT61OlQ4PCEQvF2=	MYjTRW5ITVJ?
KY821	MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPRTWM2OD1zLkW2OlE4KM7:TR?=	NETwcVNUSU6JRWK=
RH-1	M3;R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P4RWlEPTB;MT61Olc3OiEQvF2=	MnHMV2FPT0WU
KYSE-270	NX\YcI51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXmPJpvUUN3ME2xMlU4PDJ\|IN88US=>	MUnTRW5ITVJ?
SF539	NHS3THJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknZTWM2OD1zLkW3PVY6KM7:TR?=	MlmzV2FPT0WU
JEG-3	NX7UdlAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFwNUiwPVQh\|ryP	NGfQRY1USU6JRWK=
SCC-25	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;VXHlKSzVyPUGuOVg1OzJizszN	M3Txd3NCVkeHUh?=
SW1573	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwNkCxOVgh\|ryP	M3rkbXNCVkeHUh?=
EW-1	NWPub2VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PTeWlEPTB;MT62NVM2OSEQvF2=	M4nRVXNCVkeHUh?=
YKG-1	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LQVWlEPTB;MT62NVQ{QCEQvF2=	NXXCR5JoW0GQR1XS
EW-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTFwNkG3OFEh\|ryP	NUPoO5A6W0GQR1XS
DJM-1	M1\ZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO2OZZKSzVyPUGuOlE5OjVizszN	MnL3V2FPT0WU
Calu-3	M3LCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFT1[3ZKSzVyPUGuOlUzOTNizszN	NF\tUYtUSU6JRWK=
HT-3	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjLVVVKUUN3ME2xMlY2PjZizszN	NU[wPZFPW0GQR1XS
NCI-H69	M3vMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIe3doNKSzVyPUGuOlc{PDNizszN	NWqzUWlJW0GQR1XS
NCI-H2126	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnu1TWM2OD1zLk[3O\|k4KM7:TR?=	MW\TRW5ITVJ?
RPMI-2650	M1rYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7ZRpFKSzVyPUGuOlg{OTdizszN	MmXzV2FPT0WU
TE-6	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTFwN{C4O\|Qh\|ryP	MWDTRW5ITVJ?
MDA-MB-231	M4G4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzwTWM2OD1zLkexPVk{KM7:TR?=	MXrTRW5ITVJ?
A2780	NGHYZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{W3eGlEPTB;MT63NlIxPyEQvF2=	MU\TRW5ITVJ?
GOTO	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvJTWM2OD1zLkezOVYh\|ryP	MmnzV2FPT0WU
KYSE-70	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO4Tm46UUN3ME2xMlc1PDR{IN88US=>	NES2fYNUSU6JRWK=
GMS-10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTOTWM2OD1zLke0OlYzKM7:TR?=	MlvzV2FPT0WU
CaR-1	M3f6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4CydmlEPTB;MT63OFgyOiEQvF2=	MmTYV2FPT0WU
SW900	NFKycYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTFwN{S5PVMh\|ryP	MXPTRW5ITVJ?
BB49-HNC	NILSXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTUPXRKSzVyPUGuO\|UyPjhizszN	NVXCR4JyW0GQR1XS
SNB75	NYniOJBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTFwN{W0PVIh\|ryP	NYfyd4NDW0GQR1XS
SK-PN-DW	NGLYWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnUXHdsUUN3ME2xMlc2Pjh{IN88US=>	NWjRR5JwW0GQR1XS
5637	NUiyTY9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFwN{eyOlgh\|ryP	M3nIZ3NCVkeHUh?=
BT-474	NHnZe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTFwN{ixO\|Eh\|ryP	NWT4eWNYW0GQR1XS
KM12	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfI[XBKSzVyPUGuO\|k4PDFizszN	MVXTRW5ITVJ?
COLO-680N	NEDQOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIWyU2tKSzVyPUGuPFI{QDFizszN	MW\TRW5ITVJ?
Saos-2	NILHcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrWfItKSzVyPUGuPFI1PDVizszN	M4LFN3NCVkeHUh?=
CAL-54	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnPcnFKSzVyPUGuPFM{OTNizszN	MVPTRW5ITVJ?
U-118-MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmGxTWM2OD1zLki0OlIzKM7:TR?=	MUDTRW5ITVJ?
TGBC24TKB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwOEW1NFEh\|ryP	NHz4dJNUSU6JRWK=
NCI-H2052	NGSx[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTwcZZHUUN3ME2xMlg3PDFizszN	NUXNR\|VFW0GQR1XS
BB30-HNC	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnewTWM2OD1zLki2OFYzKM7:TR?=	NFn3bpBUSU6JRWK=
KNS-81-FD	NEfoVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PTcGlEPTB;MT64PVE3PSEQvF2=	MWXTRW5ITVJ?
HN	M2e2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLjO3NKUUN3ME2xMlg6PTR3IN88US=>	M2[wN3NCVkeHUh?=
ACHN	NUm0[I82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwOUC3PFYh\|ryP	NIT4[ZFUSU6JRWK=
HSC-2	NIf5b2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLVdGJKSzVyPUGuPVExQTZizszN	NXnh[VdrW0GQR1XS
HCC2998	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGSw[2dKSzVyPUGuPVM{OjVizszN	M1z4PXNCVkeHUh?=
HEL	NGPCOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTYT4MyUUN3ME2xMlk1OTh2IN88US=>	NVfRNIIxW0GQR1XS
SW684	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmS0TWM2OD1zLkm3N\|cyKM7:TR?=	NHzJ[ohUSU6JRWK=
NCI-H1693	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH4TWM2OD1zLkm4NFg3KM7:TR?=	MU\TRW5ITVJ?
8-MG-BA	NXnKe4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrwTWM2OD1zLkm4NlEh\|ryP	NUjS[ZlOW0GQR1XS
OVCAR-8	M17Jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3mxXWlEPTB;Mj6wNFI6PSEQvF2=	Ml7NV2FPT0WU
DSH1	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvpc5dSUUN3ME2yMlAyPzd2IN88US=>	NIXuPWhUSU6JRWK=
KYSE-520	M2TvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3HeJFFUUN3ME2yMlAzODR7IN88US=>	MXPTRW5ITVJ?
GB-1	M4DMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJwMEK1O\|ch\|ryP	NHnyWWlUSU6JRWK=
RCC10RGB	NEHOXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJwMES4O\|Eh\|ryP	M1j0TnNCVkeHUh?=
SW954	NWXC[GtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vJPWlEPTB;Mj6wOVA{PiEQvF2=	NVjydVZsW0GQR1XS
IST-MES1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHuTWM2OD1{LkC1OVY5KM7:TR?=	MX;TRW5ITVJ?
AU565	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPjSmpKSzVyPUKuNFU6ODVizszN	Mk\sV2FPT0WU
CW-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJwME[4O\|Uh\|ryP	MULTRW5ITVJ?
TE-1	NHjHZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnVTWM2OD1{LkC5N\|c4KM7:TR?=	M{fVO3NCVkeHUh?=
KP-4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfhclBTUUN3ME2yMlExOzF{IN88US=>	NW\hcHJFW0GQR1XS
SNU-C2B	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\O[oZUUUN3ME2yMlExQDJ\|IN88US=>	MUDTRW5ITVJ?
NCI-H1395	M3rpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkH3TWM2OD1{LkGwPVg3KM7:TR?=	MXzTRW5ITVJ?
CAS-1	NWH0OodxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjxWGdRUUN3ME2yMlEyPTR4IN88US=>	NWH2bpVrW0GQR1XS
NCI-H1155	NH\Obo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\oVYU3UUN3ME2yMlIzPjlizszN	M4OyXXNCVkeHUh?=
SK-MEL-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljITWM2OD1{LkK4NVgyKM7:TR?=	MlywV2FPT0WU
KINGS-1	NWHLOJhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M173NGlEPTB;Mj6zNFA5QCEQvF2=	MmW0V2FPT0WU
ESS-1	M1HFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;zTGFCUUN3ME2yMlMxPTFizszN	MkHqV2FPT0WU
PANC-10-05	M13mNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJwM{ewNlQh\|ryP	MmrsV2FPT0WU
HT-1376	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC3TWM2OD1{LkO4O\|A5KM7:TR?=	NGXHTGhUSU6JRWK=
LS-513	M2LFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDOOFkyUUN3ME2yMlM5QDd2IN88US=>	NFrrNHNUSU6JRWK=
KNS-42	NXy5SVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkO0TWM2OD1{LkO5NVA2KM7:TR?=	NEWwRpdUSU6JRWK=
639-V	NVHsVZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XocGlEPTB;Mj60Nlc2QCEQvF2=	NXPwXJNWW0GQR1XS
SJRH30	NGK4ZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmSwTWM2OD1{LkS1NVYyKM7:TR?=	NUDYdndOW0GQR1XS
SW1783	NXH6WphrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPUcGlqUUN3ME2yMlQ4ODd6IN88US=>	M1\KfXNCVkeHUh?=
NB6	NVvuZZluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHkTWM2OD1{LkS4Nlgh\|ryP	MX;TRW5ITVJ?
SK-MEL-30	NWjTW4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml6wTWM2OD1{LkS4PFMh\|ryP	NGDOW4tUSU6JRWK=
HCE-4	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHKT5hKSzVyPUKuOFk1ODJizszN	NFrwR4RUSU6JRWK=
NB10	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVi2Z41qUUN3ME2yMlQ6PDJ7IN88US=>	NGPoTJhUSU6JRWK=
H-EMC-SS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\rOXZKSzVyPUKuOVQ3PSEQvF2=	M{XEcXNCVkeHUh?=
SK-HEP-1	M13YZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLRT401UUN3ME2yMlU2OjN4IN88US=>	NX;0WZNjW0GQR1XS
HCC1395	M3PDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJwNUW2OVUh\|ryP	M{Ow[XNCVkeHUh?=
HuCCT1	NGnUXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPGSWtKSzVyPUKuOVY{QSEQvF2=	MWLTRW5ITVJ?
SiHa	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJwNUi3NVkh\|ryP	M3[1[HNCVkeHUh?=
EFO-21	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTJwNUi3OlQh\|ryP	M{D6UHNCVkeHUh?=
NCI-H1666	NW\JbJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDTdIdKSzVyPUKuOVkxPzZizszN	MV3TRW5ITVJ?
UMC-11	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrheIRKSzVyPUKuOVk5PjhizszN	MV7TRW5ITVJ?
COLO-679	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEH0UHJKSzVyPUKuOlEzOzNizszN	MlHCV2FPT0WU
A388	M1jTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXWWVdsUUN3ME2yMlY2OjV\|IN88US=>	MVjTRW5ITVJ?
LB2518-MEL	NVXFS5dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;3TWM2OD1{Lk[1OFA5KM7:TR?=	NHzJeZBUSU6JRWK=
EW-13	M2nLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7qbYs6UUN3ME2yMlY5PzZ6IN88US=>	MXjTRW5ITVJ?
MLMA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTmXpdMUUN3ME2yMlY5QDV4IN88US=>	NHrP[YJUSU6JRWK=
HOP-92	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJwN{CxNUDPxE1?	MYPTRW5ITVJ?
NOMO-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\JOWlEPTB;Mj63NVQ1OiEQvF2=	NYHDSmRMW0GQR1XS
NCI-H810	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW1TWM2OD1{LkeyNVk5KM7:TR?=	NYLwe\|BjW0GQR1XS
769-P	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfGOHZKSzVyPUKuO\|IzQCEQvF2=	MUXTRW5ITVJ?
SAS	NEjhU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEG3bZRKSzVyPUKuO\|Y2KM7:TR?=	Ml[wV2FPT0WU
M059J	NGDkPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXFb2lKSzVyPUKuO\|g{OThizszN	Moe1V2FPT0WU
RD	NInnbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\MXmlEPTB;Mj63PVQ4OSEQvF2=	MWTTRW5ITVJ?
GT3TKB	M1;sdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\sPZFKSzVyPUKuPFM1OzNizszN	NH3pVHpUSU6JRWK=
MZ7-mel	M4r3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7NV3BKSzVyPUKuPFY2ODJizszN	NUf6WoJyW0GQR1XS
KYSE-510	M1;SeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmX2TWM2OD1{Lki5OVA1KM7:TR?=	MX;TRW5ITVJ?
NCI-N87	NFXlNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;CT4lKSzVyPUKuPVE5ODdizszN	NXjHWWxUW0GQR1XS
MKN1	NGTZTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUj1Vo15UUN3ME2zMlAxOTZ\|IN88US=>	MXXTRW5ITVJ?
NCI-H2170	NVTzfW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XTRmlEPTB;Mz6wNFQ2OSEQvF2=	MXfTRW5ITVJ?
OVCAR-3	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLETWM2OD1\|LkCyNVE2KM7:TR?=	MofxV2FPT0WU
KLE	M{[2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnrTWM2OD1\|LkC2PFEzKM7:TR?=	NX3OOYFwW0GQR1XS
LB771-HNC	NHi2SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrxTWM2OD1\|LkC5N\|Q{KM7:TR?=	NIT6WpZUSU6JRWK=
MC116	NUHGTnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknWTWM2OD1\|LkGxNVEzKM7:TR?=	M2nqOXNCVkeHUh?=
SCC-9	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTNwMUGzOlYh\|ryP	NFz3VI1USU6JRWK=
U031	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HxN2lEPTB;Mz6xNlQzOyEQvF2=	NYH3OGhPW0GQR1XS
LCLC-103H	NEPGOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\PbnZKSzVyPUOuNlM5QTRizszN	NF7K[YRUSU6JRWK=
U-266	NXrmfnhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjx[XZGUUN3ME2zMlI4PjN\|IN88US=>	MmLSV2FPT0WU
JVM-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTNwM{KxOlQh\|ryP	NGP3NnhUSU6JRWK=
UACC-257	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTNwNE[0N\|Eh\|ryP	NVHVT481W0GQR1XS
LB996-RCC	M17Hd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLMb4NsUUN3ME2zMlQ3PTB{IN88US=>	MoDRV2FPT0WU
BT-549	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XnbmlEPTB;Mz61NFIxQSEQvF2=	NVrlW49QW0GQR1XS
NCI-H526	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{K0RWlEPTB;Mz61OFE2QCEQvF2=	NV3C[GlGW0GQR1XS
RH-18	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEWyZWRKSzVyPUOuOlE4QThizszN	MmG2V2FPT0WU
SW626	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTNwN{GxNlgh\|ryP	MnTQV2FPT0WU
SK-N-AS	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\XTWM2OD1\|LkezNlQ4KM7:TR?=	MnjYV2FPT0WU
IGR-1	NV\acHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3q3NGlEPTB;Mz63OFI1QCEQvF2=	NVvDRWZEW0GQR1XS
NCI-H2291	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHoTWM2OD1\|Lke1N\|M3KM7:TR?=	MVnTRW5ITVJ?
NCI-H441	NXS4SohrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DIbGlEPTB;Mz64NlQ{OyEQvF2=	MU\TRW5ITVJ?
D-247MG	M{\0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrRfGdKSzVyPUOuPFYxOzFizszN	M2\kTnNCVkeHUh?=
COLO-320-HSR	NEfJNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTNwOUGyO\|Eh\|ryP	MkeyV2FPT0WU
A253	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7vU3RGUUN3ME2zMlkyPDN4IN88US=>	M1qzO3NCVkeHUh?=
HT55	NF7pWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHWfnJKSzVyPUOuPVE4PzNizszN	MlO1V2FPT0WU
MZ1-PC	NFjYXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTNwOUW4OlQh\|ryP	NVT2PFlPW0GQR1XS
RERF-LC-MS	NEPtVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvsTWM2OD1\|Lkm2OVI2KM7:TR?=	NHvVV2lUSU6JRWK=
SF268	NX\TWWNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\PTWM2OD12LkGyPFgyKM7:TR?=	M4O4TnNCVkeHUh?=
RMG-I	M3Hzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzBeXE{UUN3ME20MlIyPDV2IN88US=>	NGGzTZdUSU6JRWK=
CFPAC-1	NXfzPXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTRwMkG2PFUh\|ryP	NF;se5BUSU6JRWK=
S-117	M3OzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnoclFRUUN3ME20MlIzODJ2IN88US=>	M3rXV3NCVkeHUh?=
NCI-H2122	NYrHU\|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTRwM{C5N\|Eh\|ryP	NFzsPXBUSU6JRWK=
J82	M2rHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfFW2VUUUN3ME20MlM{PDRzIN88US=>	MUXTRW5ITVJ?
CAL-72	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\uV\|hKSzVyPUSuN\|U1PzdizszN	MXfTRW5ITVJ?
GP5d	NITpelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXOzUXBGUUN3ME20MlQyOjl6IN88US=>	M2T6T3NCVkeHUh?=
UACC-62	NVfiO2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33yWWlEPTB;ND60OlU1PSEQvF2=	MXjTRW5ITVJ?
MS-1	NGjsdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnmfZhKSzVyPUSuOFkyOTVizszN	MVfTRW5ITVJ?
RCM-1	NV3SdpRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3qTWM2OD12LkWyPVIh\|ryP	MVHTRW5ITVJ?
IST-SL1	NU\1VGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{S2cWlEPTB;ND62OVM2QSEQvF2=	M1jHT3NCVkeHUh?=
SW756	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnsTWM2OD12Lk[5NVM2KM7:TR?=	MY\TRW5ITVJ?
HCC38	MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vqXmlEPTB;ND63NVE6PyEQvF2=	NHKyN45USU6JRWK=
YAPC	NGHHNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;PdmlEPTB;ND63NVMyOyEQvF2=	NGfYSotUSU6JRWK=
DK-MG	M{LvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkK3TWM2OD12Lke4NVEzKM7:TR?=	MYHTRW5ITVJ?
HCC1937	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\2TWM2OD12Lki1NVI2KM7:TR?=	MmrMV2FPT0WU
OAW-28	M{LsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HzOWlEPTB;ND65NlQ{PSEQvF2=	NX\mTnhrW0GQR1XS
MEG-01	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGi1Z3BKSzVyPUWuNFg{OjhizszN	MoTUV2FPT0WU
GI-1	M2HEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXWbpJmUUN3ME21MlI{PDh4IN88US=>	M3XOeHNCVkeHUh?=
FADU	NFnYOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO3[GtbUUN3ME21MlI4QDN5IN88US=>	MVLTRW5ITVJ?
CAPAN-1	M37hemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\MSGlEPTB;NT6zPVQ{OiEQvF2=	M{\BSnNCVkeHUh?=
TGBC11TKB	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TWV2lEPTB;NT60OVc5PiEQvF2=	MnnIV2FPT0WU
DBTRG-05MG	NUfkU3J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTVwNUC1NkDPxE1?	M2iw[3NCVkeHUh?=
ONS-76	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXLe5ZnUUN3ME21MlU2QDBzIN88US=>	MYLTRW5ITVJ?
Ca-Ski	NEeyOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXL3PYd[UUN3ME21MlYzPTZ4IN88US=>	MXrTRW5ITVJ?
COLO-741	NFvjbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH1dopKSzVyPUWuO\|E6QTVizszN	MWPTRW5ITVJ?
HT-29	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XRWmlEPTB;NT64NFQ4PSEQvF2=	NXLrSJB3W0GQR1XS
HCC1187	M{jOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTVwOEGwNFgh\|ryP	NWfYcXl5W0GQR1XS
Capan-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LIOWlEPTB;NT65OVk6PCEQvF2=	M{THUHNCVkeHUh?=
NCI-H630	NICwUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHhVFhKSzVyPU[uNVE1PDFizszN	MnrXV2FPT0WU
COLO-678	NI\yeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjETFRFUUN3ME22MlE2ODl{IN88US=>	M17zc3NCVkeHUh?=
D-502MG	M4rKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\qWGRKSzVyPU[uNVc{OzZizszN	NXLiVplLW0GQR1XS
NB17	M1LpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4X6XmlEPTB;Nj6yOFk1OyEQvF2=	M{jjVnNCVkeHUh?=
SK-MEL-24	M2T2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTZwMk[0PUDPxE1?	M{fF[HNCVkeHUh?=
NCI-SNU-5	NF3rcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7iblFZUUN3ME22MlI4OTF6IN88US=>	M3;yNXNCVkeHUh?=
D-392MG	NGXrTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTZwM{OzPVkh\|ryP	MmftV2FPT0WU
A498	NGjONGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTZwNECzNFIh\|ryP	MYTTRW5ITVJ?
OCI-AML2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j3W2lEPTB;Nj60OVQ1PSEQvF2=	M{jWVXNCVkeHUh?=
HCC2157	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\6WYdoUUN3ME22MlQ2PjF4IN88US=>	M3uxT3NCVkeHUh?=
C3A	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknRTWM2OD14LkWyNFA1KM7:TR?=	MkHDV2FPT0WU
NCI-H1650	M3jtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEK0ZmVKSzVyPU[uO\|A2OjJizszN	Mn\LV2FPT0WU
DU-145	NIPzZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{H6SWlEPTB;Nj63O\|A{KM7:TR?=	NYDSVY1DW0GQR1XS
COLO-829	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTZwN{e4O\|Mh\|ryP	M3TSNXNCVkeHUh?=
LS-1034	M4\XWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGO2dXRKSzVyPUeuNFQ1OTJizszN	NHy2d\|dUSU6JRWK=
HCC1954	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTdwNEixN\|Qh\|ryP	NXzHb2Y6W0GQR1XS
KURAMOCHI	M4nqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7YTWM2OD15LkS4OVM{KM7:TR?=	MoruV2FPT0WU
Mo-T	NHjDTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\kXWVSUUN3ME23MlUyPDl6IN88US=>	MWXTRW5ITVJ?
OE19	NH:2XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTdwNkW1NFMh\|ryP	NEPIeGxUSU6JRWK=
COR-L105	NWCwPIt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoGzTWM2OD15LkexOFIyKM7:TR?=	MlTFV2FPT0WU
NCI-H2342	M1\Xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHQPWJqUUN3ME23MlcyPTJzIN88US=>	M{\jTXNCVkeHUh?=
U-87-MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrYTWM2OD16LkCzN\|M1KM7:TR?=	MmGwV2FPT0WU
MKN28	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRThwMUG1NVUh\|ryP	M3XWWnNCVkeHUh?=
HT-1197	NYHNUI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPpNWNKSzVyPUiuNlU6ODdizszN	M4XJRXNCVkeHUh?=
ChaGo-K-1	M1WyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn5VZhKSzVyPUiuN\|QzPDVizszN	M3[4ZXNCVkeHUh?=
NCI-H226	NHW2UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnkTWM2OD16LkS0N\|MyKM7:TR?=	MnvqV2FPT0WU
NCI-H2029	M3jlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zSOWlEPTB;OT6wOlc2QSEQvF2=	MkPGV2FPT0WU
TE-11	NGPx[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnLOI1KSzVyPUmuOFU2QDhizszN	NFTPb41USU6JRWK=
ZR-75-30	M{LOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED0XWZKSzVyPUmuPVI3OzRizszN	NUjqVJBKW0GQR1XS
SW837	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFyLkKyPVMh\|ryP	M3\EVXNCVkeHUh?=
NCI-H1651	NX7qV4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFyLkKzNlYh\|ryP	MmLZV2FPT0WU
NCI-H727	M2j4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;sTZVKSzVyPUGwMlQ1QTVizszN	MYnTRW5ITVJ?
NCI-H358	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTFyLkizOlUh\|ryP	M4jDVHNCVkeHUh?=
NCI-H2087	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[4TWM2OD1zMT6wOFM1KM7:TR?=	MVHTRW5ITVJ?
FTC-133	M{H1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorDTWM2OD1zMT60NFUyKM7:TR?=	MVLTRW5ITVJ?
LAN-6	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDYTWM2OD1zMj6xNlQh\|ryP	M2HrcHNCVkeHUh?=
NCI-H1838	M17W[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13uRWlEPTB;MUKuOVE2OSEQvF2=	MljXV2FPT0WU
Calu-6	M1\ab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTF2LkGwNlEh\|ryP	NUDJW5l6W0GQR1XS
HCC70	NFPSbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTF2LkS1NUDPxE1?	MlrpV2FPT0WU
KARPAS-299	M3\PfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXTTWM2OD1zNT6yNVU6KM7:TR?=	NHXFRnlUSU6JRWK=
CAL-27	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fnWGlEPTB;MUWuN\|g1OyEQvF2=	MVjTRW5ITVJ?
NCI-H82	NHrFOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPnTWM2OD1zNT61N\|Ih\|ryP	MYfTRW5ITVJ?
no-10	M{e5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF3LkmzPEDPxE1?	NFzWd2pUSU6JRWK=
U251	M4LVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF4LkO2O\|Uh\|ryP	NXy3eVBCW0GQR1XS
TE-9	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HXT2lEPTB;MUeuOVE3PiEQvF2=	M{O4XnNCVkeHUh?=
TE-10	M1LiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\xfmFQUUN3ME2xPU4xPjB5IN88US=>	MmXUV2FPT0WU
COLO-824	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LwTWlEPTB;MkCuPVI4PiEQvF2=	MVXTRW5ITVJ?
HuP-T3	Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1f1ZWlEPTB;MkGuNFc1QCEQvF2=	NU\JN3hlW0GQR1XS
KALS-1	NULjb25MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLmTWM2OD1{MT6xO\|Uh\|ryP	M37kZXNCVkeHUh?=
L-428	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HJbmlEPTB;MkGuOFAyPiEQvF2=	NYn2WVg1W0GQR1XS
JAR	NYDjfoFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJzLkWwNkDPxE1?	Mki4V2FPT0WU
DoTc2-4510	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLEd\|M1UUN3ME2yN{45PDd3IN88US=>	M{jXfHNCVkeHUh?=
ABC-1	M1XEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPrTWM2OD1{Nj63PVU4KM7:TR?=	NHrJfnpUSU6JRWK=
MHH-NB-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXHTWM2OD1\|Mz6zOFY1KM7:TR?=	MWjTRW5ITVJ?
SW1463	M3vWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojXTWM2OD1\|Mz65PFMh\|ryP	NFrocZZUSU6JRWK=
SW1417	NWPHcWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;COmlEPTB;M{euNFk2OiEQvF2=	MYXTRW5ITVJ?
NB12	NVv3fYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljjTWM2OD1\|OT60OlU2KM7:TR?=	M33LTXNCVkeHUh?=
NY	NF3weGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXTTWM2OD12MT6zNlAyKM7:TR?=	NYPwOpdSW0GQR1XS
H1048	NX7iWWdiSXCxcITvd4l{KEG\|c3H5	MlK5OVAxKG6P	NGiwWHg4OiCq		NWjBeHRMdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	M{L1dFI2PzN5NUSy
H86	M2juS2Fxd3C2b4Ppd{BCe3OjeR?=	M2PiXVUxOCCwTR?=	MWS3NkBp		NFL0N\|RvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	M17qVVI2PzN5NUSy
H196	NXTtNXo6SXCxcITvd4l{KEG\|c3H5	NGXzfI82ODBibl2=	NXj1[YhzPzJiaB?=		M4PJXI5p[W6lZYOgRWJVNTJ4M,MAl4lv\HWlZXSgZZBweHSxc3nz	M{OwbFI2PzN5NUSy
H446	MX7BdI9xfG:\|aYOgRZN{[Xl?	NXjFZlNEPTByIH7N	NU\ER5RbPzJiaB?=		MULubIFv[2W\|IFHCWE0zPjQkgKPpcoR2[2WmIHHwc5B1d3Orcx?=	NHrOWIIzPTd\|N{W0Ni=>
TFK-1	NVSwSZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYi3NkBp	NXjwUZNZTE2VTx?=	NUjJPI1PUUN3ME20O{BvVQ>?	MkjhNlUyPTJ{NES=
EGI-1	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{G5VFczKGh?	NULxNmdvTE2VTx?=	NYrJfGR6UUN3ME21N{BvVQ>?	NXLCfW5ROjVzNUKyOFQ>
OCI/AML3	NF7SO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37MU\|AvOiEQvF2=	M3fYXlQ5KGh?		MnHG[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IIPlcJVu\XSrbnni	NV\FXlJHOjR5M{mzPVM>
U937	MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2wMlIh\|ryP	MWq0PEBp		MUXlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	Mn;3NlQ4Ozl\|OUO=
MOLM13	NUWyTll{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\VW2ZGOC5{IN88US=>	NIPUbWQ1QCCq		M135b4VvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDz[Yx2dWW2aX7pZi=>	NFrmW3QzPDd\|OUO5Ny=>
MCF7	NFT0e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSyNEBvVQ>?	MonBO\|IhcA>?	M{XYWmZDWw>?	M{Tve5Jm\HWlZYOgeIhmKFCHTGCxMY1m\GmjdHXkJIlv[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5	MmTNNlQ3QDhyNE[=
TamR	NWLPVYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPWV49rUUN3ME2xPQKBkW6P	M2HweVI1PDV5ME[5
MCF7-X	NVLieFRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTzZ\|N2UUN3ME2yOEBvVQ>?	MXSyOFQ2PzB4OR?=
T47D-tamR	NFrh[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX4TWM2OD1zOTDuUS=>	NFfnNYgzPDR3N{C2PS=>
293T	MlPKSpVv[3Srb36gRZN{[Xl?	MWOyNEBvVQ>?	NX3nZo9JOyCq		NF3O[5VlcXO{dYD0d{BCc3RvbXXkbYF1\WRiVFnGMWlCKHO2YXLpcIl1gSxidILhcpNtd2OjdHnvckwh[W6mIHHjeIl3cXS7	M1[1NVI1OzZ\|NES5
SW620	NFLFVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW[wMlAxOS1zMN88US=>	MlXVNlQhcA>?		Mn7VbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjczD0bIUh[2:wY3XueJJifGmxbjDybZNmew>?	NITidpYzPDN4M{S0PS=>
Huh7	NEjUVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGD5c2E2NTFyMDDuUS=>	MUKwMVI1KGh?	MWDEUXNQ	MoTRbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NG\lUFIzPDJ7N{OwNC=>
Hep3B	NFvRdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV71VIo1PS1zMECgcm0>	MkfRNE0zPCCq	NH;TbFhFVVOR	MXXpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NUDNRplVOjR{OUezNFA>
Huh7	NWPyd3JJTnWwY4Tpc44hSXO\|YYm=	NGrOXooyODBibl2=	MoHBNVIhcA>?	NHzu[2RFVVOR	M3\2Uolv\HWlZYOgZZV1d3CqYXf5xsA>	NGXJdZMzPDJ7N{OwNC=>
U87-MG	NXW5fIY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4HZb\|czKGh?		NULuTGFtT0l3MPMAjV3jiIl5OTDuUeKh	NHrlfFEzPDJ2OU[0NC=>
L3.6pl	NWnqdnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXVb41QOSEQvF2=	NWnrSnl2PzJiaB?=		M1HM[4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEKPUz23O\|c3ODd?	NEfHO\|gzPDJ\|M{O5PS=>
TE671	MoPhRZBweHSxc3nzJGF{e2G7	NIHNSo4yKM7:TR?=	NV7LUYZlPDhiaB?=		MUHpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	NXTleGNKOjRzM{OyNVg>
RD	M134XWFxd3C2b4Ppd{BCe3OjeR?=	NFjhU4wyKM7:TR?=	MnrtOFghcA>?		M2jpZolv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	MofTNlQyOzN{MUi=
RMS13	MVrBdI9xfG:\|aYOgRZN{[Xl?	NF[2OmcyKM7:TR?=	M4LUNVQ5KGh?		M3HHSYlv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	MlPkNlQyOzN{MUi=
RH30	MoDFRZBweHSxc3nzJGF{e2G7	M1XK[lEh\|ryP	NFjUOWQ1QCCq		Mn\PbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	MX:yOFE{OzJzOB?=
Hep-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\yVIwxNjBzLUGg{txO	MUixNk06PiCq		MnLObY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NWHHfXR2OjRzMEO3OFk>
SCC-9	M{XzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\QcVAvODFvMTFOwG0>	M2Gx[FEzNTl4IHi=		MmDmbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NInuOYQzPDFyM{e0PS=>
Hep-2	MU\GeY5kfGmxbjDBd5NigQ>?	NYD6fWEzOC5zL{CuOUDPxE1?	MmmyNlQhcA>?		M4jYeIJtd2OtczDtWG9TSzFiYX7kJI1VV1KFMjDhZ5RqfmG2aX;u	MX[yOFExOzd2OR?=
SCC-9	M37GfmZ2dmO2aX;uJGF{e2G7	NV3pTm12OC5zL{CuOUDPxE1?	NITkUVkzPCCq		M3XjRYJtd2OtczDtWG9TSzFiYX7kJI1VV1KFMjDhZ5RqfmG2aX;u	NVjJXI0yOjRzMEO3OFk>
PANC-1	NUPxPYNsSXCxcITvd4l{KEG\|c3H5	NUDn[XlZPTByIH7N	M1q1dlQ5KGh?		Mn;Gd4Vve2m2aYrld{Bx[W6lcnXheIlkKGOjbnPldkBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	NXTSTJp1OjN6OE[yPVQ>
RMG2	MYHBdI9xfG:\|aYOgRZN{[Xl?	NFLCZZoyNTFyMECgcm0>	NF3yNm44OiCq	MWDGRnM>	NY\nO45ucW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	MoDaNlM3OTV4M{G=
HAC2	M3TWVmFxd3C2b4Ppd{BCe3OjeR?=	NF7JU5cyNTFyMECgcm0>	NIrzcnE4OiCq	MYDGRnM>	MYfpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	NXG2SVRnOjN4MUW2N\|E>
HT-29	M4n6eGFxd3C2b4Ppd{BCe3OjeR?=	M{HJVlEh\|ryP	NYfUbmk6PzJiaB?=		NITpWlRifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	Ml7oNlE6PDlzMkG=
DLD1	M{L3[GFxd3C2b4Ppd{BCe3OjeR?=	Mmm1NUDPxE1?	NVTON\|R1PzJiaB?=		NHP3N4NifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	NYjPRmtNOjF7NEmxNlE>
HT-29	NV\uNmN5TnWwY4Tpc44hSXO\|YYm=	Ml;rNUDPxE1?	M3P2SlczKGh?		MY\pcoR2[2W\|IHH1eI9xcGGpeTD0c{Bkd26oZYKgZ5l1d3C{b4TlZ5Rqd25?	NY[wdXljOjF7NEmxNlE>
DLD1	MnvTSpVv[3Srb36gRZN{[Xl?	NUfx[3N6OSEQvF2=	MYq3NkBp		NUfCWHRDcW6mdXPld{BifXSxcHjh[5khfG9iY3;u[oVzKGO7dH;wdo91\WO2aX;u	MUiyNVk1QTF{MR?=
Rh41	NH20XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPZUHJlUUN3ME2zNE44KG6P	NVXDWmY5OjF\|M{e2O\|k>
Rh18	M1q1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTRzLkSgcm0>	NWK4OWw2OjF\|M{e2O\|k>
Rh30	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXT[GIzUUN3ME2xOEBvVQ>?	MWWyNVM{PzZ5OR?=
BT-12	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPNWJdKSzVyPUK0Mlchdk1?	M13P[\|IyOzN5Nke5
CHLA-266	M4PPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn1N2pKSzVyPUGuNUBvVQ>?	MUSyNVM{PzZ5OR?=
TC-71	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjYTWM2OD12Nj61JI5O	M{PmT\|IyOzN5Nke5
CHLA-9	NF;IWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnpZZBkUUN3ME2xOU4{KG6P	M2DFRVIyOzN5Nke5
CHLA-10	NX\LTXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;oV\|ZsUUN3ME2zMlkhdk1?	NVmyWGdWOjF\|M{e2O\|k>
CHLA-258	M332V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDWTWM2OD1zMD60JI5O	MmjrNlE{Ozd4N{m=
GBM2	M2fCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvuTWM2OD12MD63JI5O	NEKxUGUzOTN\|N{[3PS=>
NB-1643	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTN\|Lkigcm0>	M{nv[VIyOzN5Nke5
NB-EBc1	M13QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\0R2lEPTB;MkeuNUBvVQ>?	M{Hs[lIyOzN5Nke5
CHLA-90	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjMRXZUUUN3ME2zOE42KG6P	NFXlTFgzOTN\|N{[3PS=>
CHLA-136	M{fyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7xRmlxUUN3ME2xOlIvPiCwTR?=	MYWyNVM{PzZ5OR?=
NALM-6	NVy0OYE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnNTWM2OD1\|Mj65JI5O	NYrSWFE6OjF\|M{e2O\|k>
COG-LL-317	M17xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV70OpRQUUN3ME2xMlMhdk1?	M1:5NVIyOzN5Nke5
RS4;11	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHPSpJnUUN3ME2zOUBvVQ>?	NVfhNFR1OjF\|M{e2O\|k>
MOLT-4	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHyTWM2OD16Lk[gcm0>	MmTJNlE{Ozd4N{m=
CCRF-CEM	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3kTWM2OD12LkGgcm0>	MYeyNVM{PzZ5OR?=
Kasumi-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTFwNDDuUS=>	M33jWFIyOzN5Nke5
Karpas-299	M1;QOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17GbWlEPTB;MkGuO{BvVQ>?	NHPMSXMzOTN\|N{[3PS=>
Ramos-RA1	MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1u5bWlEPTB;OD6yJI5O	MnH1NlE{Ozd4N{m=
H838	NEm2SVFHfW6ldHnvckBCe3OjeR?=	Ml\LNUDPxE1?	NWPmRWRbPDhiaB?=		MVLpcoR2[2W\|IHPlcIwh[XW2b4DoZYd6	MnniNlA{PjRzMUO=
H838	NILl[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3DbmYxNTNizszN	NUfsSVB6PzJiaB?=		NF3Z[pNqdmS3Y3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CCjdYTvdIhi\3l?	M2rOUlIxODJ6OEW0
A549	M4[2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFriWIsxNTNizszN	NFrIOWE4OiCq		MlTobY5lfWOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh[XW2b4DoZYd6	MnvyNlAxOjh6NUS=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	- Collapse Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- Collapse

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 113 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 113 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)